{
    "2018-03-15": [
        [
            {
                "time": "2018-03-01",
                "original_text": "Analysts’ Recommendations for Eli Lilly in March 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "analysts",
                        "recommendations"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-05",
                "original_text": "Update on Eli Lilly’s Oncology Drugs Erbitux, Gemzar, Lartruvo",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "oncology drugs",
                        "Erbitux",
                        "Gemzar",
                        "Lartruvo"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-07",
                "original_text": "Performance of Eli Lilly’s Oncology Drugs Alimta, Cyramza in 2017",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "performance",
                        "Alimta",
                        "Cyramza"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-10",
                "original_text": "Update on Eli Lilly’s Neuroscience Portfolio",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "neuroscience",
                        "portfolio"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "neuroscience"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-12",
                "original_text": "Eli Lilly’s Immunology Business Saw Solid Growth in 2017",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "immunology",
                        "solid growth"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "immunology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)",
                "features": {
                    "keywords": [
                        "Cramer",
                        "Mad Money",
                        "recap"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}